Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 18/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 18/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 18/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.62 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652941 | 0.79 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653420 | 0.78 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653236 | 0.78 | GABRG2 (0.63) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652630 | 0.78 | GABRG2 (0.64) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL221868 | 0.78 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3625237 | 0.78 | HSD17B1 (0.74) | HSD17B1HSD17B2 | |
| SCHEMBL2654763 | 0.78 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2652903 | 0.77 | GABRG2 (0.55) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| Pyridazine SCHEMBL4034767 | 0.76 | GABRG2 (0.54) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2654358 | 0.74 | GABRG2 (0.62) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | claimed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | claimed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| EP-1532120-B1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRG2 20/4885GABRB3 8/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.